Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

Yolanda Escobar, Gerardo Cajaraville, Juan Antonio Virizuela, Rosa Álvarez, Andrés Muñoz, Olatz Olariaga, María José Tamés, Begoña Muros, María Jose Lecumberri, Jaime Feliu, Purificación Martínez, Juan Carlos Adansa, María José Martínez, Rafael López, Ana Blasco, Pere Gascón, Virginia Calvo, Pablo Luna, Joaquín Montalar, Patricia Del Barrio, María Victoria Tornamira, Yolanda Escobar, Gerardo Cajaraville, Juan Antonio Virizuela, Rosa Álvarez, Andrés Muñoz, Olatz Olariaga, María José Tamés, Begoña Muros, María Jose Lecumberri, Jaime Feliu, Purificación Martínez, Juan Carlos Adansa, María José Martínez, Rafael López, Ana Blasco, Pere Gascón, Virginia Calvo, Pablo Luna, Joaquín Montalar, Patricia Del Barrio, María Victoria Tornamira

Abstract

Purpose: This study aims to determine the incidence of nausea and vomiting (CINV) after moderately emetogenic chemotherapy (MEC), under medical practice conditions and the accuracy with which physicians perceive CINV.

Methods: Chemotherapy-naive patients receiving MEC between April 2012 and May 2013 were included. Patients completed a diary of the intensity of nausea and number of vomiting episodes. Complete response and complete protection were assessed as secondary endpoints.

Results: Of 261 patients included, 240 were evaluated. Median age was 64 years, 44.2 % were female and 11.2 % were aged less than 50 years; 95.3 % of patients received a combination of 5-hydroxytryptamine 3 (5-HT3) antagonist + corticosteroid as antiemetic treatment. Vomiting within 5 days of chemotherapy administration occurred in 20.8 %, nausea in 42 % and significant nausea in 23.8 % of patients. An increase in the percentage of patients with significant nausea (from 9.4 to 21.7 %) and vomiting (from 9.2 to 16.5 %) was observed from the acute to the delayed phase. Complete response was 84.2 % in the acute phase, 77 % in the late phase and 68.9 % in overall period. Complete protection was 79.5 % in the acute phase, 68.8 % in the late phase and 62.4 % throughout the study period. Physicians estimated prophylaxis would be effective for 75 % of patients receiving MEC, compared with 54.1 % obtained from patients' diary.

Conclusion: Despite receiving prophylactic treatment, 31 % of patients did not achieve a complete response and 38 % complete protection. In general, nausea was worse controlled than vomiting. The results also showed the late phase was worse controlled than the acute phase in all variables. Healthcare providers overestimated the effectiveness of antiemetic prophylaxis.

Figures

Fig. 1
Fig. 1
Incidence CINV
Fig. 2
Fig. 2
Patients with complete response and complete protection
Fig. 3
Fig. 3
Physicians’ perception vs. study results

References

    1. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH. On the receiving end patient perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19:203–208. doi: 10.1016/0277-5379(83)90418-2.
    1. de Boer-Dennert M, de Wit R, Schmitz PIM, Djontono J, van Beurden V, Stoter G, Verweij J. Patient perception of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer. 1997;76:1055–1061. doi: 10.1038/bjc.1997.507.
    1. Passik SD, Kirsh KL, Rosenfeld B, McDonald MV, Theobald DE. The changeable nature of patients’ fear regarding chemotherapy: implications for palliative care. J Pain Symptom Manag. 2001;21:113–120. doi: 10.1016/S0885-3924(00)00249-9.
    1. Wagland R, Richardson A, Armes J, Hankins M, Lennan E, Griffiths P (2014) Treatment-related problems experienced by cancer patients undergoing chemotherapy: a scoping review Eur J Cancer Care. doi: 10.1111/ecc.12246
    1. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189–4198. doi: 10.1200/JCO.2010.34.4614.
    1. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(suppl 5):v232–v243. doi: 10.1093/annonc/mdq194.
    1. Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol. 2011;22:30–8. doi: 10.1093/annonc/mdq600.
    1. Hesketh PJ. Drug therapy: chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482–2494. doi: 10.1056/NEJMra0706547.
    1. Jordan K, Gralla R, Jahn F, Molassiotis A. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol. 2014;722:197–202. doi: 10.1016/j.ejphar.2013.09.073.
    1. Roscoe JA, Morrow GR, Hickok JT, Stern RM. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manag. 2000;20:113–121. doi: 10.1016/S0885-3924(00)00159-7.
    1. Perwitasari DA, Atthobari J, Mustofa M, Dwiprahasto I, Hakimi M, Gelderblom H, Putter H, Nortier JW, Guchelaar HJ, Kaptein AA. Impact of chemotherapy-induced nausea and vomiting on quality of life in Indonesian patients with gynecologic cancer. Int J Gynecol Cancer. 2012;22:139–45. doi: 10.1097/IGC.0b013e318234f9ee.
    1. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472–4478. doi: 10.1200/JCO.2006.05.6382.
    1. Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer. 2012;20:107–117. doi: 10.1007/s00520-010-1073-9.
    1. Diario y Agenda Personal de Salud. Sociedad Española de Oncología Médica (SEOM) y Sociedad Española de Enfermería Oncológica (SEEO) 2008.
    1. Basch E, Snyder C, McNiff K, Brown R, Maddux S, Smith ML, Atkinson TM, Howell D, Chiang A, Wood W, Levitan N, Wu AW, Krzyzanowska M. Patient-reported outcome performance measures in oncology. J Oncol Pract. 2014;10:209–211. doi: 10.1200/JOP.2014.001423.
    1. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100:2261–2268. doi: 10.1002/cncr.20230.
    1. Gómez-Raposo C, Feliú-Batle J, González-Barón M. Prevención y control de las náuseas y vómitos inducidos por quimioterapia. Med Clin. 2006;126:143–51. doi: 10.1157/13084022.
    1. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, On behalf of the Aprepitant Protocol 054 Study Group Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer. 2003;97:3090–3098. doi: 10.1002/cncr.11433.
    1. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocol 052 Study Group The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol. 2003;21:4112–9. doi: 10.1200/JCO.2003.01.095.
    1. Hsieh RK, Chan A, Kim HK, Yu S, Kim JG, Lee MA, Dalén J, Jung H, Liu YP, Burke TA, Keefe DM. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer. 2015;23:263–72. doi: 10.1007/s00520-014-2373-2.
    1. Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 2003;8:187–98. doi: 10.1634/theoncologist.8-2-187.
    1. Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F, on behalf of the PEER investigators The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER) Ann Oncol. 2012;23:1986–1992. doi: 10.1093/annonc/mds021.
    1. Antiemesis. NCCN practice guidelines in oncology v2 2014. National Comprehensive Cancer Network . Last accessed September 4, 2014
    1. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932–47. doi: 10.1200/JCO.2006.06.9591.
    1. Navari RM. Overview of the updated antiemetic guidelines for chemotherapy-induced nausea and vomiting. Commun Oncol. 2007;4:3–11.
    1. De Angelis V, Roila F, Sabbatini R, Italian Group for Antiemetic Research et al. Cancer chemotherapy (CT)-induced delayed emesis: antiemetic prescriptions in clinical practice (abstract 2971) J Clin Oncol. 2003;22:739.
    1. Rubenstein EB, Litke SE, Jose MA (2002) Chemotherapy-induced nausea and emesis in the 5HT3 era: a national survey of hematologists/oncologists [abstract]. Proc Am Soc Clin Oncol 21:260b
    1. Majem M, Moreno ME, Calvo N, Feliu A, Pérez J, Mangues MA, Barnadas A. Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Cancer Care. 2011;19:1983–90. doi: 10.1007/s00520-010-1042-3.
    1. Kris MG. Why do we need another antiemetic? Just Ask. J Clin Oncol. 2003;21:4077–80. doi: 10.1200/JCO.2003.07.968.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit